Literature DB >> 16531617

The charisma of subgroups and the subgroups of CHARISMA.

Marc A Pfeffer, John A Jarcho.   

Abstract

Mesh:

Substances:

Year:  2006        PMID: 16531617     DOI: 10.1056/NEJMe068061

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  8 in total

1.  Analysis of randomized comparative clinical trial data for personalized treatment selections.

Authors:  Tianxi Cai; Lu Tian; Peggy H Wong; L J Wei
Journal:  Biostatistics       Date:  2010-09-28       Impact factor: 5.899

Review 2.  Role of antiplatelet therapy in secondary prevention of acute coronary syndrome.

Authors:  Mathieu Pankert; Jacques Quilici; Thomas Cuisset
Journal:  J Cardiovasc Transl Res       Date:  2011-11-06       Impact factor: 4.132

3.  EFFECTIVELY SELECTING A TARGET POPULATION FOR A FUTURE COMPARATIVE STUDY.

Authors:  Lihui Zhao; Lu Tian; Tianxi Cai; Brian Claggett; L J Wei
Journal:  J Am Stat Assoc       Date:  2013-01-01       Impact factor: 5.033

4.  Contemporary use of dual antiplatelet therapy for preventing cardiovascular events.

Authors:  Andrew M Goldsweig; Kimberly J Reid; Kensey Gosch; Fengming Tang; Margaret C Fang; Thomas M Maddox; Paul S Chan; David J Cohen; Jersey Chen
Journal:  Am J Manag Care       Date:  2014-08       Impact factor: 2.229

Review 5.  Clopidogrel: a review of its use in the prevention of thrombosis.

Authors:  Greg L Plosker; Katherine A Lyseng-Williamson
Journal:  Drugs       Date:  2007       Impact factor: 9.546

Review 6.  Safety of clopidogrel and aspirin for stroke prevention: implications of the CHARISMA trial.

Authors:  Sean Ruland
Journal:  Drug Saf       Date:  2008       Impact factor: 5.606

7.  Subgroup specific incremental value of new markers for risk prediction.

Authors:  Qian M Zhou; Yingye Zheng; Tianxi Cai
Journal:  Lifetime Data Anal       Date:  2012-12-23       Impact factor: 1.588

8.  Outcome based subgroup analysis: a neglected concern.

Authors:  Karim F Hirji; Morten W Fagerland
Journal:  Trials       Date:  2009-05-20       Impact factor: 2.279

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.